SCHEMBL5038826

SCHEMBL5038826

Cc1ccc(-c2ccccc2B(O)O)cc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
ALDH1A1 P00352 7/20 0.47
HSD17B10 Q99714 1/20 0.46
TSHR P16473 2/20 0.45
CYP3A4 P08684 1/20 0.45
RECQL P46063 1/20 0.45
MAPT P10636 6/20 0.45
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
MAPK1 P28482 2/20 0.45
LMNA P02545 1/20 0.45
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
PPIA P62937 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12117513 0.83 HSD17B10 (0.58) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL5216747 0.78 TSHR (0.55) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL29957061 0.77 HTR7 (0.47) CES2CES1MAPTKMT2AMEN1
SCHEMBL17157028 0.77 ALDH1A1 (0.52) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL7190826 0.77 TSHR (0.64) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL21839417 0.76 HTR7 (0.49) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL15203036 0.76 CRHBP (0.58) CES2CES1ALDH1A1HSD17B10TSHR
SCHEMBL29623123 0.76 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP3A4MAPTKMT2A
SCHEMBL20187601 0.76 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP3A4MAPTKMT2A
SCHEMBL1514401 0.76 CRHBP (0.58) CES2CES1ALDH1A1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410963-B2 To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile VIA PHARMACEUTICALS, INC. (US) 2008-08-12 US disclosed
US-20070123519-A1 Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof BAY CITY CAPITAL LLC 2007-05-31 US disclosed
EP-1697332-A1 BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF NEURO3D (FR) 2006-09-06 EP disclosed
WO-2005063723-A1 BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF NEURO3D (FR) 2005-07-14 WO disclosed
EP-1548011-A1 Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof NEURO3D (FR) 2005-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123519-A1 Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof PDE12, PDE2A, PDE3A CES2 61/4885CES1 118/4885ALDH1A1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.